Abstract：
During the past five years, many states have imposed out-of-pocket spending caps on insulin. In most cases, these reforms have had limited impact, in part because of the limits of state authority. Meanwhile, changes at the federal level and actions by manufacturers and commercial plans have made some of the caps nonbinding. It is not surprising that efforts to measure the impact of these caps yield conflicting results.
摘要：
在过去的五年里,许多州对胰岛素实行了自费支出上限。在大多数情况下,这些改革影响有限，部分原因是国家权力的限制。同时,联邦一级的变化以及制造商和商业计划的行动使一些上限不具约束力。衡量这些上限影响的努力产生了相互矛盾的结果，这并不奇怪。
